Physician profile
Sanjeev Gupta
NPI 1558360693
$2,738.25
in general payments reported to CMS, 2019-2025
32 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $361 · 2021: $446 · 2022: $262 · 2023: $533 · 2024: $368 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $455.34 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $393.72 | 2019-2020 | |
| Glaxosmithkline, LLC. | $228.17 | 2021-2023 | Bexsero |
| Medtronic Minimed, INC. | $177.25 | 2019 | |
| Novo Nordisk INC | $161.07 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Corium, LLC | $154.80 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $145.54 | 2019-2025 | Gardasil 9, Vaqta, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.66 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Teva Pharmaceuticals USA, INC. | $104.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.81 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $71.66 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $67.51 | 2019-2024 | |
| Pfizer INC. | $62.27 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $59.57 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $49.63 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $45.64 | 2022-2024 | Freestyle Libre 2 |
| Sobi, INC | $43.64 | 2023 | |
| Alnylam Pharmaceuticals INC. | $35.33 | 2024 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.56 | 2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $28.34 | 2019 | |
| Dexcom, INC. | $20.44 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $19.75 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.70 | 2025 | Caplyta |
| Lundbeck LLC | $19.62 | 2022 | |
| Owp Pharmaceuticals, INC. | $19.02 | 2023 | Subvenite, Lamotrigine |
| Biohaven Pharmaceuticals, INC. | $17.86 | 2021 | |
| Abbvie INC. | $17.60 | 2023 | |
| Eisai INC. | $14.84 | 2022 | |
| Circassia INC. | $13.66 | 2019 | |
| Lilly USA, LLC | $13.49 | 2020 | |
| Adlon Therapeutics L.P. | $13.47 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.